<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000258356"><TermName>gefitinib</TermName><TermPronunciation>(geh-FIH-tih-nib)</TermPronunciation><TermDefinition><DefinitionText>A drug that is used to treat certain types of non-small cell lung cancer and is being studied in the treatment of other types of cancer. It is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called Iressa and ZD1839.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000710150" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;gefitinib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000710149" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;gefitinib&quot;" language="es" id="_4"/><SpanishTermName>gefitinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para el tratamiento de ciertos tipos de cánceres de pulmón de células no pequeñas y que se estudia para el tratamiento de otros tipos de cáncer. Es un tipo de inhibidor de la tirosina cinasa del receptor del factor de crecimiento epidérmico (RFCE). También se llama Iressa y ZD1839.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateLastModified>2007-06-18</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000495775">Gefitinib</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
